<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="136288">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02057380</url>
  </required_header>
  <id_info>
    <org_study_id>7487-CL-0209</org_study_id>
    <secondary_id>2013-004076-34</secondary_id>
    <nct_id>NCT02057380</nct_id>
  </id_info>
  <brief_title>A Rollover Study for Subjects That Have Participated in an Astellas Sponsored Linsitinib Trial</brief_title>
  <official_title>A Phase II Open-label Rollover Study for Subjects That Have Participated in an Astellas Sponsored Linsitinib Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Astellas Pharma Global Development, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Astellas Pharma Inc</source>
  <oversight_info>
    <authority>Brazil: National Health Surveillance Agency</authority>
    <authority>Czech Republic: State Institute for Drug Control</authority>
    <authority>Germany: Federal Institute for Drugs and Medical Devices</authority>
    <authority>Poland: Office for Registration of Medicinal Products, Medical Devices and Biocidal Products</authority>
    <authority>Romania: National Agency for Medicines and Medical Devices</authority>
    <authority>Russia: Ministry of Health of the Russian Federation</authority>
    <authority>Singapore: Health Sciences Authority</authority>
    <authority>Thailand: Food and Drug Administration</authority>
    <authority>United Kingdom: Medicines and Healthcare Products Regulatory Agency</authority>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to provide access to continued treatment for subjects who
      participated in other Astellas sponsored trials and for whom the investigator feels the
      subject may benefit from continued treatment.
    </textblock>
  </brief_summary>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date>March 2014</start_date>
  <completion_date type="Anticipated">December 2015</completion_date>
  <primary_completion_date type="Anticipated">December 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Number of subjects with adverse events</measure>
    <time_frame>24 months</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <number_of_arms>7</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Advanced Solid Tumors</condition>
  <arm_group>
    <arm_group_label>Arm A:  Medium dose linsitinib twice daily monotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Arm A includes subjects from Protocol OSI-906-301</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B:Medium dose linsitinib twice daily plus high dose erlot</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Arm B includes subjects from Protocol OSI-906-205</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm C:  High dose erlotinib monotherapy once daily</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Arm C includes subjects from Protocol OSI-906-205 and OSI-906-207</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm D:Medium dose linsitinib twice daily plus weekly paclitaxe</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Arm D includes subjects from Protocol OSI-906-202</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm E:High dose linsitinib intermittent once daily on Days 1-3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Arm E includes subjects from Protocol OSI-906-202</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm F:  Paclitaxel alone weekly</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Arm F includes subjects from Protocol OSI-906-202</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm G: Low dose linsitinib twice daily plus low dose erlotinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Arm G includes subjects from Protocol OSI-906-103</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>linsitinib</intervention_name>
    <description>oral</description>
    <arm_group_label>Arm A:  Medium dose linsitinib twice daily monotherapy</arm_group_label>
    <arm_group_label>Arm B:Medium dose linsitinib twice daily plus high dose erlot</arm_group_label>
    <arm_group_label>Arm D:Medium dose linsitinib twice daily plus weekly paclitaxe</arm_group_label>
    <arm_group_label>Arm E:High dose linsitinib intermittent once daily on Days 1-3</arm_group_label>
    <arm_group_label>Arm G: Low dose linsitinib twice daily plus low dose erlotinib</arm_group_label>
    <other_name>OSI-906</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>erlotinib</intervention_name>
    <description>oral</description>
    <arm_group_label>Arm B:Medium dose linsitinib twice daily plus high dose erlot</arm_group_label>
    <arm_group_label>Arm C:  High dose erlotinib monotherapy once daily</arm_group_label>
    <arm_group_label>Arm G: Low dose linsitinib twice daily plus low dose erlotinib</arm_group_label>
    <other_name>Tarceva</other_name>
    <other_name>OSI-774</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>paclitaxel</intervention_name>
    <description>Intravenous (IV) infusion</description>
    <arm_group_label>Arm D:Medium dose linsitinib twice daily plus weekly paclitaxe</arm_group_label>
    <arm_group_label>Arm E:High dose linsitinib intermittent once daily on Days 1-3</arm_group_label>
    <arm_group_label>Arm F:  Paclitaxel alone weekly</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject must currently be participating in an Astellas sponsored linsitinib trial
             that has ended with respect to the overall study analysis.

          -  Subject must not have met criteria for discontinuation or have progressed on the
             current linsitinib study in which they are participating.

          -  Subject must be deriving benefit from continued treatment.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Executive Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Astellas Pharma Global Development, Inc.</affiliation>
  </overall_official>
  <verification_date>March 2014</verification_date>
  <lastchanged_date>March 13, 2014</lastchanged_date>
  <firstreceived_date>February 5, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Linsitinib</keyword>
  <keyword>OSI-906</keyword>
  <keyword>Erlotinib</keyword>
  <keyword>OSI-774</keyword>
  <keyword>Tarceva</keyword>
  <keyword>Paclitaxel</keyword>
  <keyword>Advanced Solid Tumor</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Erlotinib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
